Skip to content
OpenCapital
Get started

Intellia Therapeutics NTLA Reduction Of Right Of Use Assets From Remeasurement Of Lease Liabilities

Other financials

Income statement

See full
Revenue$15.0M-9.5%
Operating income-$100.5M+16.8%
Net income-$96.2M+15.8%
EPS (diluted)-$0.81+26.4%

Balance sheet

See full
Cash & equivalents$134.7M+6.2%
Total debt$80.5M-32.5%
Total equity$620.9M-20.4%
Total assets$758.8M-23.1%

Cash flow

See full
Operating cash flow-$117.3M+21.2%
CapEx$79.0K-89.3%
Free cash flow-$117.4M+21.5%

Valuation

See full
Market cap$2.17B+106%

Profitability

See full
Operating margin-636.6%-202pp
Net margin-597%-194pp
FCF margin-550.2%-140pp

Returns & leverage

See full
Return on equity-56.3%-1.5pp
Debt / equity0.1×0.0×
Current ratio6.1×+1.2×

Where this comes from

Reported directly by Intellia Therapeutics in its filing.

Tagged under the XBRL concept ntla:ReductionOfRightOfUseAssetsFromRemeasurementOfLeaseLiabilities.

The official record: Intellia Therapeutics’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →

Questions, answered.

What is Intellia Therapeutics's reduction of right of use assets from remeasurement of lease liabilities?
Intellia Therapeutics (NTLA) reported reduction of right of use assets from remeasurement of lease liabilities of $0 in Q1 2026.
How has Intellia Therapeutics's reduction of right of use assets from remeasurement of lease liabilities changed year-over-year?
Intellia Therapeutics's reduction of right of use assets from remeasurement of lease liabilities decreased by 100.0% year-over-year, from $61.92M to $0.